-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amivantamab in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Metastatic Breast Cancer Drug Details: Amivantamab-vmjw (Rybrevant) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amivantamab in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Metastatic Ovarian Cancer Drug Details: Amivantamab-vmjw (Rybrevant) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amivantamab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Amivantamab-vmjw...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amivantamab in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Amivantamab-vmjw...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amivantamab in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Recurrent Head And Neck...
-
Product Insights
Infusion Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Infusion Systems Pipeline Market Report Overview Infusion systems are used to administer medication to a patients in critical care, emergency care, home care, and trauma centres. The infusion systems pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials....
-
Sector Analysis
Infusion Pumps Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Infusion Pumps Market Overview The infusion pumps market size was valued at $2.64 billion in 2023. The infusion pumps market will grow at a CAGR of more than 2% from 2023 to 2033. The infusion pump is a commonly used medical device for patients with chronic conditions such as cancer and diabetes used at hospitals, homes, and healthcare centers. Infusion pumps successfully address the delivery-related problems that have serious implications on patient safety, with their ability to administer fluids, medication,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6468 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6468 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6468 in Solid Tumor Drug Details: RG-6468 (RO-7566802) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBM-C30.1 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBM-C30.1 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBM-C30.1 in Non-Hodgkin Lymphoma Drug Details: CBM-C30.1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ronopterin in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ronopterin in Traumatic Brain Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ronopterin in Traumatic Brain Injury Drug Details: Ronopterin (VAS-203) is...